Sartorius Stedim Biotech S.A. Investor Relations

A Trusted Partner for the Biopharmaceutical Industry and Laboratories

Sartorius Stedim Biotech is a leading international partner for the biopharma sector. Our solutions are supporting our customers to develop and produce drugs safely, timely and economically. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies.

Seven reasons to invest

  • Clear focus on the attractive biopharma sector
  • Long-term growth drivers and significant market entrance barriers
  • Market leading position in key technologies and recognized brand
  • High share of recurring revenue as well as diversified earnings base
  • Strong presence in growth regions
  • Proven track record with alliances and acquisitions
  • High continuity with respect to customer base, employees and management

Sartorius Stedim Biotech | Q1 2022 Results

  • Sales revenue up 27.6 percent in constant currencies, underlying EBITDA margin 35.2 percent
  • Healthy demand situation; normalization of pandemic-related effects and development of order intake, as expected; extensive investment program on schedule
  • Positioning strengthened by acquisition of chromatography business from Novasep
  • Outlook for 2022 confirmed: Sales revenue expected to rise by 15 to 19 percent and underlying EBITDA margin projected to be more than 35 percent
  • Global political and economic uncertainties substantially increased

Earnings Release

Financial Data

Conference Call Presentation

Conference Call Audio

Documents

Investors Presentation Q1 2022 Results

PDF 3.1 MB

IR Factsheet Q1|2022

PDF 115.8 KB

Annual Report 2021

PDF 4.0 MB

Half-Year Report H1|2021

PDF 1015.8 KB

About Sartorius Stedim Biotech

Learn More

Strategy and Targets for 2025

Sartorius Stedim Biotech’s goal is to continue its profitable growth and systematically expand its position as a leading international partner for biopharmaceutical research and the industry. We are pursuing various strategic initiatives to grow sustainably up to 2025 – and beyond.

In 2018, management presented its strategy and long-term targets up to 2025. The consolidated sales revenue target was again significantly raised at the beginning of 2021 and so was the profitability target at the start of 2022. Accordingly, Sartorius Stedim Biotech plans to increase consolidated sales revenue to about €4 billion by 2025 and to reach an underlying EBITDA margin of more than 35% (previously around 33%). The company intends to achieve this increase primarily through organic growth and additionally by acquisitions.

The mid-term targets for 2025 still do not include any pandemic-related business as management currently considers such estimates to be too uncertain.

The margin targets already include expenses for measures to reduce the company’s CO2 emission intensity. Sartorius Stedim Biotech aims to reduce its CO2 emission intensity by around 10% annually on average until 2030, spending over time around 1% of its sales revenue annually for corresponding measures. Moreover, these projections assume that, on average, the margins of future acquisitions will initially be somewhat below the levels of the Group’s existing businesses and, after integration, at levels comparable to these, and that there will be no relevant changes in the key currency exchange rates.

Management points out that the dynamics and volatilities in the life science and biopharma sectors have increased over the past years and the coronavirus pandemic has further amplified these trends so that forecasts show even higher uncertainties than usual.


1 Sartorius Stedim Biotech publishes alternative performance measures that are not defined by international accounting standards. These are determined with the aim of improving the comparability of business performance over time and within the industry

  • Underlying EBITDA: earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items
  • Order intake: all customer orders contractually concluded and booked during the respective reporting period
  • Relevant / underlying net profit: profit for the period after non-controlling interest; adjusted for extraordinary items and non-cash amortization, as well as based on a normalized financial result and a normalized tax rate
  • Underlying earnings per share: relevant / underlying net profit for the period divided by the number of shares outstanding
  • Ratio of net debt to underlying EBITDA: quotient of net debt and underlying EBITDA over the past 12 months, including the pro forma amount contributed by acquisitions for this period
  • CAPEX ratio: investment payments in relation to sales revenue for the same period

We focus in both divisions on the attractive biopharmaceutical market characterized by long‑term and stable growth trends.

Key Growth Drivers

  • Growing world population
  • Increasing incomes and better access to healthcare services in emerging economies
  • Aging population and rise in age-related diseases in industrialized countries

Medical progress is also fueling growth, resulting in the ongoing development and approval of new biopharmaceuticals and in the improvement or expansion of indications for already existing active pharmaceutical ingredients. Therefore, a growing number of biotech medications are being approved for treatment of rare diseases considered incurable until now, and innovative cell and gene therapies are projected to further drive growth in the biopharma sector.

Sartorius Stedim Biotech has leading market positions in core technologies and is continuously expanding its portfolio by new, complementary technologies that help our biopharma customers develop and manufacture medications faster and more easily. Our strength in selecting suitable partners or acquisition candidates is based upon our in-depth understanding of applications. We are thoroughly familiar with our customers’ requirements and their entire value-added chains, and particularly understand the interactivity of the systems they use. Our innovation strategy is based on three pillars:

  • Integration of innovations through acquisitions
  • Alliances with partners
  • Own product development

Due to exceptionally strong organic growth, Sartorius Stedim Biotech invested considerably in building up production capacities in the reporting year, and therefore moved already planned expansion projects ahead of schedule as well as accelerated and extended these. In 2021, capital expenditures were used for planning or expanding sites in Germany, Puerto Rico, China and South Korea, among others.

North America and Asia are the key focal areas of our regional growth strategy. The USA is the world's largest market for bioprocess equipment. Yet because it is home to our main competitors, Sartorius Stedim Biotech formerly had lower market share in this region than in Europe and Asia. Over the past years, we have gained market share in the USA by strengthening our sales and service capacities and see further development potential.

A further strategic focus is on China. This market has sizable growth potential owing to rising private and public healthcare expenditures and the rapid development of regional biopharmaceutical plants. To benefit from the dynamic development of this market, Sartorius Stedim Biotech has already been investing heavily in expanding its production capacities. This especially applies to South Korea that offers strong growth prospects in this region, given its dynamically growing biopharma market. For that reason, Sartorius Stedim Biotech planned a new production facility on which construction is scheduled to begin in the current fiscal year.

Sartorius Stedim Biotech expects dynamic performance for the full year of 2022 as well. Consolidated sales revenue is thus projected to increase by about 15% to 19%. The acquisitions closed or agreed upon in 2021 are forecasted to contribute about 2 percentage points of non-organic growth to this increase. Following the jump in profitability in 2021, the company expects its underlying EBITDA margin to stay at a similarly high level and to reach more than 35%.

Regarding pandemic-related business, management projects sales revenue for 2022 at the previous year’s level of around €500 million.

The margin targets already include expenses for measures to reduce the company’s CO2 emission intensity; these expenses will account for about 0.5% of consolidated sales revenue in 2022.

Against the backdrop of strong organic growth, Sartorius Stedim Biotech is currently expanding its capacities considerably in all regions. Accordingly, capital expenditures in relation to sales revenue, the CAPEX ratio, is estimated to be around 14.5%.

The ratio of net debt to underlying EBITDA is expected to be around 0.2 at year-end, without taking any potential further acquisitions into account. All forecasts are based on constant currencies, as in the past years, and assume that the global economy as well as supply chains will remain stable.

Sartorius Stedim Biotech S.A. is the parent company of the Sartorius Stedim Biotech Group. It is headquartered in Aubagne, France, and listed on the Euronext Paris.


Approximately 74% of the share capital and around 85% of the voting rights of Sartorius Stedim Biotech S.A. are held by Sartorius AG. Sartorius AG is a leading international bioprocess and laboratory equipment and technology provider headquartered in Göttingen, Germany, and listed on the Frankfurt Stock Exchange. It operates two divisions: the bioprocess business as a subgroup under its parent corporation Sartorius Stedim Biotech S.A. and the laboratory business as a further subgroup.

Downloads

First-Quarter Results January to March 2022

April 21, 2022

Financial Publications 

Learn More

Get in Touch

Petra Kirchhoff
Head of Corporate Communications & Investor Relations
Mirko Koch
Manager Investor Relations

Financial Calendar

Financial Calendar

Learn More

Top News Sartorius Stedim Biotech

First-quarter results 2022 of Sartorius Stedim Biotech

Sartorius Stedim Biotech, a leading partner of the biopharma industry, recorded a dynamic start to fiscal 2022, with sales revenue and earnings postin...

Read More

Sartorius Stedim Biotech presents annual report for 2021

Sartorius Stedim Biotech, a leading partner of the biopharma industry, today has presented its Universal Registration Document 2021 including the Annu...

Read More

Preliminary results 2021 of Sartorius Stedim Biotech

January 27, 2022 – Sartorius Stedim Biotech closed fiscal 2021 with exceptionally strong growth and a jump in profitability.

Read More

More Information

Newsroom

Learn More

Facts & Figures

Learn More

Investor Relations Sartorius AG

Learn More